Publication & Citation Trends
Publications
85 total
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial OA
Cited by 73
Semantic Scholar
Pegozafermin for the Treatment of Severe Hypertriglyceridemia: A Randomized, Double-blind, Placebo-controlled Phase 2 Study (ENTRIGUE STUDY)
Cited by 0
Semantic Scholar
† Pegozafermin for the Treatment of Severe Hypertriglyceridemia, a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (ENTRIGUE STUDY)
Cited by 0
Semantic Scholar
Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)
Cited by 1
Semantic Scholar
PEGOZAFERMIN PROVIDES BENEFICIAL LIPID EFFECTS IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA REGARDLESS OF BACKGROUND LIPID MODIFYING THERAPY STATUS: AN ANALYSIS OF THE PHASE 2 ENTRIGUE STUDY OA
Cited by 2
Semantic Scholar
Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
Cited by 2
Semantic Scholar
Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH)
Cited by 1
Semantic Scholar
Research Topics
Liver Disease Diagnosis and Treatment
(17)
Multiple Myeloma Research and Treatments
(16)
Cancer Treatment and Pharmacology
(12)
Fibroblast Growth Factor Research
(12)
Colorectal Cancer Screening and Detection
(9)
Affiliations
Boston University
University of Southern California
Brigham and Women's Hospital
Dartmouth–Hitchcock Medical Center
Amgen (United States)